First-in-Human trial tests 'Living Drug' for autoimmune conditions
NCT ID NCT06680037
Summary
This is an early-stage safety study testing a new CAR T-cell therapy called azercabtagene zapreleucel for people with B-cell mediated autoimmune disorders like progressive multiple sclerosis. The main goal is to find the safest and most effective dose for future studies by monitoring side effects in 32 participants. This approach uses genetically modified immune cells to target and potentially control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TG Therapeutics Investigational Trial Site
RECRUITINGLa Jolla, California, 92093, United States
-
TG Therapeutics Investigational Trial Site
NOT_YET_RECRUITINGLexington, Kentucky, 40506, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGAnn Arbor, Michigan, 48019, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGOmaha, Nebraska, 68198, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGNew York, New York, 10025, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGRochester, New York, 14642, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGCleveland, Ohio, 44195, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGColumbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.